Results 11 to 20 of about 2,655 (208)

Reducing Episodic Cluster Headaches: Focus on Galcanezumab [PDF]

Journal of Pain Research, 2020
Lanfranco Pellesi,1 Roberto De Icco,2,3 Mohammad Al-Mahdi Al-Karagholi,1 Messoud Ashina1,4 1Danish Headache Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 2Headache Science Center, IRCCS Mondino Foundation,
Pellesi L, De Icco R, Al-Karagholi MA, Ashina M   +3 more
doaj   +4 more sources

Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation [PDF]

The Journal of Headache and Pain
Background Migraine progression, particularly from episodic to chronic migraine (CM), increases disease burden and healthcare costs. Understanding the new concept of “Medication Underuse Headache” should encourage the health care provider to consider ...
Wanakorn Rattanawong, Prakit Anukoolwittaya, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Auranee Trisataya, Sekh Thanprasertsuk, Alan Rapoport   +6 more
doaj   +2 more sources

A Real-World Study of CGRP Monoclonal Antibodies for Migraine: Long-Term Effectiveness and Treatment Adherence. [PDF]

Eur J Neurol
In our 24‐month real‐world study, the mean monthly migraine days (MMDs) significantly decreased from baseline by 6.8, 7.9, 8.7, and 10.0 days at Months 3, 6, 12, and 24, respectively (all p < 0.001). Significant reductions were also observed across all time points in both episodic migraine and chronic migraine subgroups.
Suzuki K, Suzuki S, Kobayashi S, Shioda M, Fujita H, Haruyama Y, Hirata K.   +6 more
europepmc   +2 more sources

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study. [PDF]

Headache
Abstract Objective This study assesses the 3‐month effectiveness of the calcitonin gene‐related peptide monoclonal antibody galcanezumab versus traditional oral migraine preventive medications. Background Studies comparing the effectiveness of calcitonin gene‐related peptide monoclonal antibodies versus traditional oral migraine preventive medications ...
Lipton RB, Láinez MJA, Ahmed Z, Vallarino C, Novick D, Vincent M, Viktrup L, Robinson RL.   +7 more
europepmc   +2 more sources

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real-life multicenter study. [PDF]

Headache
Plain Language Summary This study shows that galcanezumab is equally effective and well‐tolerated in patients aged 65 and older as in younger patients, with a higher proportion of excellent responders in older patients. Despite having more baseline headache days, older patients responded well to the treatment, with age being linked to better outcomes ...
Peris-Subiza J, Obach V, Guisado-Alonso D, Velasco Juanes F, Álvarez Escudero R, Martín Bujanda M, Aranceta S, Ruisánchez A, Roncero N, Mínguez-Olaondo A, Echeverria A, López-Bravo A, Guerrero-Peral ÁL, García-Azorín D, Cuadrado-Godia E, Galca‐Only Study Group.   +15 more
europepmc   +2 more sources

Real-world experience with 240 mg of galcanezumab for the preventive treatment of cluster headache

The Journal of Headache and Pain, 2022
Background Galcanezumab of 300 mg monthly is the FDA approved preventive medication for cluster headache (CH) during the cluster period. Compared to the 120 mg galcanezumab syringe for the treatment of migraines, the 100 mg syringe for CH has globally ...
Heejung Mo, Byung-Kun Kim, Heui-Soo Moon, Soo-Jin Cho   +3 more
doaj   +1 more source

Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study

The Journal of Headache and Pain, 2023
Background Cluster headache is a severe and disabling primary headache disorder. Galcanezumab is a monoclonal antibody against calcitonin gene-related peptide and a preventive therapy for episodic cluster headache.
Yooha Hong, Mi-Kyoung Kang, Heui-Soo Moon, Byung-Kun Kim, Soo-Jin Cho   +4 more
doaj   +1 more source

Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal [PDF]

, 2023
: Background: Few studies compare the clinical effectiveness of the three anti-CGRP mAbs. Moreover, no studies compare their efficacy during suspension and reprisal.
Belgrado, Enrico, Cellante, Giulia, Dal Bello, Simone, Del Regno, Caterina, Ercole, Bruno Hector, Ermanis, Giovanni, Gigli, Gian Luigi, Lettieri, Christian, Merlino, Giovanni, Pez, Sara, Sportelli, Giuseppe, Tereshko, Yan, Valente, Mariarosaria, Versace, Salvatore   +13 more
core   +1 more source

Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures

The Journal of Headache and Pain, 2021
Background Galcanezumab is a monoclonal antibody (mAb) that binds calcitonin gene-related peptide (CGRP) and is indicated for the preventive treatment of migraine.
Todd J. Schwedt, Dulanji K. Kuruppu, Yan Dong, Katherine Standley, Laura Yunes-Medina, Eric Pearlman   +5 more
doaj   +1 more source

Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study

The Journal of Headache and Pain, 2023
Background The phase 3 randomized PERSIST study demonstrated the efficacy and tolerability of galcanezumab, a humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for prevention of episodic migraines.
Jiying Zhou, Lianmei Zhong, Debashish Chowdhury, Kirill Skorobogatykh, Guogang Luo, Xiaosu Yang, Mingjie Zhang, Lingli Sun, Hui Liu, Chenxi Qian, Shengyuan Yu   +10 more
doaj   +1 more source